Milestone Pharmaceuticals Inc(MIST) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:56 PM ET (Korea 10/31 08:56)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.69 | Insider Own | 1.92% | Shs Outstand | 124.5M | Perf Week | 12.62% |
| Market Cap | 0.09B | Forward P/E | - | EPS next Y | 4.74% | Insider Trans | - | Shs Float | 122.1M | Perf Month | -10.51% |
| Enterprise Value | 0.06B | PEG | - | EPS next Q | -0.22 | Inst Own | 40.04% | Short Float | 16.14% | Perf Quarter | -34.82% |
| Income | -0.08B | P/S | 38.84 | EPS this Y | -12.57% | Inst Trans | 10.28% | Short Ratio | 14.49 | Perf Half Y | -60.96% |
| Sales | 0.00B | P/B | 4.99 | EPS next 5Y | 24.87% | ROA | -73.36% | Short Interest | 19.71M | Perf YTD | -63.86% |
| Book/sh | 0.15 | P/C | 0.53 | EPS past 3/5Y | 18.24% 15.09% | ROE | -35522.62% | 52W High | -76.14% ($3.06) | Perf Year | -61.17% |
| Cash/sh | 1.37 | P/FCF | - | Sales past 3/5Y | -32.38% - | ROIC | -52.71% | 52W Low | 15.74% ($0.63) | Perf 3Y | -69.33% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 21.42% | Gross Margin | 90.7% | Volatility(W/M) | 9.94% 8.24% | Perf 5Y | -87.03% |
| Dividend TTM | - | EV/Sales | 26.54 | Sales Y/Y TTM | - | Oper. Margin | -3360.86% | ATR (14) | 0.06 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.92 | EPS Q/Q | -5.63% | Profit Margin | -3585.62% | RSI (14) | 44.67 | Recom | 1.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.13 | Sales Q/Q | - | SMA20 | -0.79% ($0.74) | Beta | 1.05 | Target Price | $5.57 |
| Payout | - | Debt/Eq | 7.78 | Earnings | 2026/8/12 | SMA50 | -18.18% ($0.89) | Rel Volume | 0.53 | Prev Close | $0.79 |
| Employees | 38 | LT Debt/Eq | 7.75 | EPS/Sales Surpr. | -7.69% -31.55% | SMA200 | -46.88% ($1.37) | Avg Volume(3M) | 1.36M | Price | $0.73 |
| IPO | 2019/5/9 | Option/Short | Yes/Yes | Trades | 1538 | Volume | 727,850 | Change | -7.55% |
Milestone Pharmaceuticals is a clinical-stage biopharmaceutical company based in Canada and the United States that focuses on developing treatments for cardiovascular diseases. Its lead candidate, etripamil, is a nasal spray formulation for patients with paroxysmal supraventricular tachycardia (PSVT) and has recently received approval from the U.S. Food and Drug Administration, moving the company into the commercialization stage. The company is expanding its pipeline to include atrial fibrillation-related indications and is also building a foundation for global commercialization through partnerships.
Over the past 1 year, on the lower side
76% below its 1-year high.
Traded less than usual. That is 53% of its average volume.
MIST has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -12.6% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $3,884. Peers typically go for $1,010.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -87.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 40.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #366 of 595 in the industry
Based on market cap of $91M.
NTHI#363 NeOnc Technologies Holdings Inc $94M PER - 
ICCC#364 Immucell Corp $93M PER 122.3 
SEER#365 Seer Inc $93M PER - MIST#366 Milestone Pharmaceuticals Inc $91M PER - 
NRXS#367 Neuraxis Inc $90M PER - 
FAQ
What kind of company is MIST?
MIST belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MIST?
The market cap of MIST is approximately $91M, ranking 4,515 within its sector.
What is the 52-week high and low for MIST?
MIST has recorded a 52-week high of $3.06 and a low of $0.63.
